Clinical Trials Logo

Filter by:
NCT ID: NCT05323201 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Start date: February 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.

NCT ID: NCT05322824 Recruiting - Cognitive Function Clinical Trials

Clinical Registration Study of Patients With Intracranial / Carotid Stenosis

Start date: January 1, 2022
Phase:
Study type: Observational

Through prospective registration and follow-up, this study will collect data of patients with intracranial/carotid stenosis, including clinical information, neuropsychological scales, multimodal magnetic resonance images. The investigators aim to analyze clinical and imaging characteristics of patients with cognitive impairment related to intracranial/carotid stenosis, in order to achieve early identification of cognitive impairment.

NCT ID: NCT05322733 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Start date: April 15, 2022
Phase: Phase 2
Study type: Interventional

This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study in order to evaluate the safety and efficacy of Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

NCT ID: NCT05322330 Recruiting - Clinical trials for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

Aim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma

NCT ID: NCT05321758 Recruiting - Crohn Disease Clinical Trials

Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease

FMT
Start date: March 22, 2020
Phase: N/A
Study type: Interventional

To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.

NCT ID: NCT05321745 Recruiting - Crohn Disease Clinical Trials

Fecal Microbiota Transplantation in Pediatric Crohn's Disease

FMT
Start date: March 22, 2022
Phase: N/A
Study type: Interventional

This study will test the safety and effectiveness of fecal microbiota transplantation (FMT) plus partial enteral nutrition (PEN) in refractory pediatric Crohn's disease (CD) who have failed conventional treatment

NCT ID: NCT05321472 Recruiting - Clinical trials for Endoscopic Retrograde Cholangiopancreatography

Artificial Intelligence-assisted Common Bile Duct Stent Selection in Endoscopic Retrograde Cholangiopancreatography

Start date: April 20, 2022
Phase:
Study type: Observational

Common bile duct stenosis is an important indication for endoscopic retrograde cholangiopancreatography(ERCP). Appropriate selection of bile duct stent size is not only conducive to successful stent implantation but also to improve the prognosis of patients. Currently, the selection of stent specifications is based on the operator's empirical estimation, which is not only not accurate but also increases the radiation exposure time, causing unnecessary harm to both the operator and the patient. Our objective is to develop an artificial intelligence algorithm to automatically select appropriate stent.

NCT ID: NCT05321316 Recruiting - Clinical trials for Urothelial Carcinoma

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Start date: May 31, 2022
Phase: N/A
Study type: Interventional

To evaluate the ability of [68Ga]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.

NCT ID: NCT05321225 Recruiting - Ischemic Stroke Clinical Trials

The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke

Start date: March 10, 2022
Phase:
Study type: Observational [Patient Registry]

Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

NCT ID: NCT05321056 Recruiting - Clinical trials for Droplet Transmission

Exposure Measurements and Interventions for Aerosol Produced by Gastrointestinal Endoscopy

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

Study objective: To clarify the risk of exposure to the exhaled aerosol droplets from patients for medical staffs during digestive endoscopy via labelling the oral mucosa with vitamin B2 solution, and evaluate the protective efficacy of personal protective equipment. Study design: This is a prospective randomized controlled study.